RECEPTOR AND KINASE MODULATOR SCREENING METHODS

The invention provides methods to identify low toxicity modulators of mitogen- activated protein kinases, particularly MAPK1 and MAPK3. Such modulators are useful to treat hyperproliferation conditions including cancers such as prostate cancer, breast cancer, liver cancer and colon cancer. Such trea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CASTELLINO, ANGELO, J, READING, CHRISTOPHER, L, WHITE, STEVEN, K
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention provides methods to identify low toxicity modulators of mitogen- activated protein kinases, particularly MAPK1 and MAPK3. Such modulators are useful to treat hyperproliferation conditions including cancers such as prostate cancer, breast cancer, liver cancer and colon cancer. Such treatments are accompanied by reduced levels of toxicity, e.g., elevated liver enzymes, which are associated with ATP binding- site-dependent MAPK inhibitors. L'invention concerne des procédés pour identifier des modulateurs à faible toxicité des protéines kinases activées par mitogènes, en particulier MAPK1 et MAPK3. De tels modulateurs sont utiles pour traiter les conditions d'hyperprolifération dont les cancers, par exemple les cancers de la prostate, du sein, du foie et du colon. De tels traitements sont accompagnés de niveaux de toxicité réduits, par ex. des enzymes du foie élevées, qui sont associés aux inhibiteurs MAPK dépendant des sites de liaison ATP.